Sprout take out stokes Apricus Bio; shares up 11%

• Thinly traded nano cap Apricus Biosciences (APRI +10.7%) bucks the market's sour mood by heading north on almost double normal volume, albeit on turnover of only 206K shares. Aggressive investors appear to be taking long positions in the hope that Sprout's success with Addyi will ripple out to other firms developing products for female sexual dysfunction. Apricus supposedly has a topical cream in development called Femprox, although there is a dearth of public information on the product candidate.
• Previously: Apricus Bio wants to build on Sprout's success with Addyi; seeks development partner for Femprox for female sexual arousal disorder (Aug. 19)